Related references
Note: Only part of the references are listed.Anacetrapib and Dalcetrapib: Two Novel Cholesteryl Ester Transfer Protein Inhibitors
Marta A. Miyares
ANNALS OF PHARMACOTHERAPY (2011)
Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia
Sandrine Caron et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
MIPOMERSEN, AN APOB SYNTHESIS INHIBITOR, EVALUATION OF POTENTIAL TO REDUCE NECESSITY FOR LIPID-APHERESIS IN PATIENTS WITH HETEROZYGOUS FH AND CAD
K. G. Parhofer et al.
ATHEROSCLEROSIS SUPPLEMENTS (2011)
Triglycerides and Cardiovascular Disease A Scientific Statement From the American Heart Association
Michael Miller et al.
CIRCULATION (2011)
Emerging Targets for the Treatment of Dyslipidemia
A. Tavridou et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Functional validation of new pathways in lipoprotein metabolism identified by human genetics
Robert C. Bauer et al.
CURRENT OPINION IN LIPIDOLOGY (2011)
Combining genome-wide data from humans and animal models of dyslipidemia and atherosclerosis
Stela Z. Berisha et al.
CURRENT OPINION IN LIPIDOLOGY (2011)
MicroRNAs in lipid metabolism
Carlos Fernandez-Hernando et al.
CURRENT OPINION IN LIPIDOLOGY (2011)
Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2
Arnold von Eckardstein et al.
CURRENT OPINION IN LIPIDOLOGY (2011)
Antisense Oligonucleotides for the Treatment of Dyslipidemia
I. Gouni-Berthold et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Lipoprotein(a): Medical Treatment Options for an Elusive Molecule
Klaus G. Parhofer
CURRENT PHARMACEUTICAL DESIGN (2011)
Emerging options in the treatment of dyslipidemias: a bright future?
Matilda Florentin et al.
EXPERT OPINION ON EMERGING DRUGS (2011)
Mipomersen, an antisense apolipoprotein B synthesis inhibitor
Damon A. Bell et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Cholesteryl Ester Transfer Protein: The Controversial Relation to Atherosclerosis and Emerging New Biological Roles
Helena C. F. Oliveira et al.
IUBMB LIFE (2011)
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis
Katey J. Rayner et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice
Adam E. Mullick et al.
JOURNAL OF LIPID RESEARCH (2011)
Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease
Esther M. M. Ooi et al.
JOURNAL OF LIPID RESEARCH (2011)
Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism
Guoping Li et al.
JOURNAL OF LIPID RESEARCH (2011)
Complexities of plasma apolipoprotein C-III metabolism
Frank M. Sacks et al.
JOURNAL OF LIPID RESEARCH (2011)
APOLIPOPROTEIN B SYNTHESIS INHIBITION BY MIPOMERSEN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL WHEN ADDED TO MAXIMALLY TOLERATED LIPID-LOWERING MEDICATION IN PATIENTS WITH SEVERE HETEROZYGOUS HYPERCHOLESTEROLEMIA
Jean Claude Tardif et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice
Esther Merki et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
SAFETY AND EFFICACY OF MIPOMERSEN ADMINISTERED AS ADD-ON THERAPY IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND HIGH CARDIOVASCULAR RISK
William C. Cromwell et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
24, 25-Dihydroxycholecalciferol but not 25-hydroxycholecalciferol suppresses apolipoprotein A-I gene expression
Kent R. Wehmeier et al.
LIFE SCIENCES (2011)
Targeting endogenous apo A-I-a new approach for raising HDL
Prediman K. Shah
NATURE REVIEWS CARDIOLOGY (2011)
Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Ariel Brautbar et al.
NATURE REVIEWS CARDIOLOGY (2011)
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms
Mohamad Navab et al.
NATURE REVIEWS CARDIOLOGY (2011)
Novel HDL-directed pharmacotherapeutic strategies
Emil M. Degoma et al.
NATURE REVIEWS CARDIOLOGY (2011)
Lowering apolipoprotein CIII delays onset of type 1 diabetes
Rebecka Holmberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
High density lipoprotein: it's not just about lipid transport anymore
Scott M. Gordon et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2011)
Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
Fatima Akdim et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
Combined Therapy of Dietary Fish Oil and Stearoyl-CoA Desaturase 1 Inhibition Prevents the Metabolic Syndrome and Atherosclerosis
J. Mark Brown et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small Apolipoproteins
Carlos O. Mendivil et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Apolipoprotein B100 biogenesis: a complex array of intracellular mechanisms regulating folding, stability, and lipoprotein assembly
Angela C. Rutledge et al.
BIOCHEMISTRY AND CELL BIOLOGY (2010)
Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction The American Heart Association's Strategic Impact Goal Through 2020 and Beyond
Donald M. Lloyd-Jones et al.
CIRCULATION (2010)
Targeting ApoB as a therapeutic approach for the treatment of dyslipidemia: the potential role of mipomersen
Tiffany Thomas et al.
CLINICAL LIPIDOLOGY (2010)
Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies
Sadik H. Kassim et al.
CLINICAL LIPIDOLOGY (2010)
Enigmatic Role of Lipoprotein(a) in Cardiovascular Disease
Erdembileg Anuurad et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2010)
Development of Apolipoprotein B Antisense Molecules as a Therapy for Hyperlipidemia
Tiffany Thomas et al.
CURRENT ATHEROSCLEROSIS REPORTS (2010)
Apolipoprotein B synthesis inhibition: results from clinical trials
Maartje E. Visser et al.
CURRENT OPINION IN LIPIDOLOGY (2010)
Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income Countries
Thomas A. Gaziano et al.
CURRENT PROBLEMS IN CARDIOLOGY (2010)
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
M. John Chapman et al.
EUROPEAN HEART JOURNAL (2010)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Inflammation reduces HDL protection against primary cardiac risk
James P. Corsetti et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2010)
Mipomersen as a potential adjunctive therapy for hypercholesterolemia
Neeraj Patel et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Nonsynonymous Mutations within APOB in Human Familial Hypobetalipoproteinemia EVIDENCE FOR FEEDBACK INHIBITION OF LIPOGENESIS AND POSTENDOPLASMIC RETICULUM DEGRADATION OF APOLIPOPROTEIN B
Shumei Zhong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Decreased Expression of ARV1 Results in Cholesterol Retention in the Endoplasmic Reticulum and Abnormal Bile Acid Metabolism
Fumin Tong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Inhibition of Acyl-Coenzyme A: Cholesterol Acyltransferase 2 (ACAT2) Prevents Dietary Cholesterol-associated Steatosis by Enhancing Hepatic Triglyceride Mobilization
Heather M. Alger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
Maartje E. Visser et al.
JOURNAL OF LIPID RESEARCH (2010)
CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance
J. Mark Brown et al.
JOURNAL OF LIPID RESEARCH (2010)
Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
Fatima Akdim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation
O. Olivieri et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Biological, clinical and population relevance of 95 loci for blood lipids
Tanya M. Teslovich et al.
NATURE (2010)
Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease
Kitt Falk Petersen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Genomewide Association Studies and Assessment of the Risk of Disease
Teri A. Manolio
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates
Ellen Marie Straarup et al.
NUCLEIC ACIDS RESEARCH (2010)
Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion
Meenakshi Sundaram et al.
NUTRITION & METABOLISM (2010)
A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
Nidhi Gupta et al.
PLOS ONE (2010)
Molecular pathways and agents for lowering LDL-cholesterol in addition to statins
Philippe Costet
PHARMACOLOGY & THERAPEUTICS (2010)
miR-33 links SREBP-2 induction to repression of sterol transporters
Tyler J. Marquart et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The Framingham Heart Study's Impact on Global Risk Assessment
Asaf Bitton et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2010)
MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis
S. Hani Najafi-Shoushtari et al.
SCIENCE (2010)
MiR-33 Contributes to the Regulation of Cholesterol Homeostasis
Katey J. Rayner et al.
SCIENCE (2010)
RNAi and small interfering RNAs in human disease therapeutic applications
Monica R. Lares et al.
TRENDS IN BIOTECHNOLOGY (2010)
microRNAs and cholesterol metabolism
Kathryn J. Moore et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Low high-density lipoprotein cholesterol: current status and future strategies for management
Vibhuti Singh et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2010)
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
Rosie Z. Yu et al.
BIOCHEMICAL PHARMACOLOGY (2009)
MicroRNAs: Target Recognition and Regulatory Functions
David P. Bartel
CELL (2009)
Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2 '-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
Rosie Z. Yu et al.
CLINICAL PHARMACOKINETICS (2009)
Triglycerides as vascular risk factors: new epidemiologic insights
William B. Kannel et al.
CURRENT OPINION IN CARDIOLOGY (2009)
Antisense oligonucleotide pharmacokinetics and metabolism
Richard S. Geary
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Ribonuclease H: the enzymes in eukaryotes
Susana M. Cerritelli et al.
FEBS JOURNAL (2009)
Specific Role for Acyl CoA:Diacylglycerol Acyltransferase 1 (Dgat1) in Hepatic Steatosis Due to Exogenous Fatty Acids
Claudio J. Villanueva et al.
HEPATOLOGY (2009)
Binding and Cleavage Specificities of Human Argonaute2
Walt F. Lima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Short Antisense Oligonucleotides with Novel 2′-4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals
Punit P. Seth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Anakinra for Rheumatoid Arthritis: A Systematic Review
Marty Mertens et al.
JOURNAL OF RHEUMATOLOGY (2009)
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Robert Clarke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats
Derek M. Erion et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice
Xing Xian Yu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
Inhibition of ADRP prevents diet-induced insulin resistance
Gladys M. Varela et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2008)
Differential regulation of apolipoprotein A-I gene expression by vitamin D receptor modulators
Kent R. Wehmeier et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2008)
Knockdown of Acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice
Ying Liu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2008)
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
Alberto Alonso-Ruiz et al.
BMC MUSCULOSKELETAL DISORDERS (2008)
Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice
Esther Merki et al.
CIRCULATION (2008)
Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis
J. Mark Brown et al.
CIRCULATION (2008)
Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction
Akio Kawakami et al.
CIRCULATION (2008)
Dyslipidemia and Atherosclerosis Induced by Chronic Intermittent Hypoxia Are Attenuated by Deficiency of Stearoyl Coenzyme A Desaturase
Vladimir Savransky et al.
CIRCULATION RESEARCH (2008)
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Esther M. M. Ooi et al.
CLINICAL SCIENCE (2008)
HDL metabolism in context: looking on the bright side
Gerald F. Watts et al.
CURRENT OPINION IN LIPIDOLOGY (2008)
Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes Epidemiology and risk factors
Carlo B. Giorda et al.
DIABETES CARE (2008)
Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster?
Vasilios G. Athyros et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models
Elizabeth P. Newberry et al.
HEPATOLOGY (2008)
An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
D. C. Chan et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Liver lipid metabolism
P. Nguyen et al.
JOURNAL OF ANIMAL PHYSIOLOGY AND ANIMAL NUTRITION (2008)
Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss
J. Mark Brown et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Inhibition of microRNA with antisense oligonucleotides
Christine C. Esau
METHODS (2008)
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Toni I. Pollin et al.
SCIENCE (2008)
Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis
Kanji Yamaguchi et al.
HEPATOLOGY (2008)
Molecular diagnosis of hypobetalipoproteinemia: An ENID review
Patrizia Tarugi et al.
ATHEROSCLEROSIS (2007)
ISIS 301012 gene therapy for hypercholesterolemia: Sense, antisense, or nonsense?
Matthew K. Ito
ANNALS OF PHARMACOTHERAPY (2007)
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance
Cheol Soo Choi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Antisense apolipoprotein B therapy: where do we stand?
Fatima Akdim et al.
CURRENT OPINION IN LIPIDOLOGY (2007)
Antisense apolipoprotein B-100 as novel treatment for hypercholesterolemia: focus on ISIS 301012
Fatima Akdim et al.
FUTURE LIPIDOLOGY (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide
Yumi Imai et al.
GASTROENTEROLOGY (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100
Rosie Z. Yu et al.
DRUG METABOLISM AND DISPOSITION (2007)
Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL
Tomas Vaisar et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
Kanji Yamaguchi et al.
HEPATOLOGY (2007)
Aberrant hepatic expression of PPARγ2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis
Yuan-Li Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Lipoprotein(a): A unique risk factor for cardiovascular disease
Erdembileg Anuurad et al.
CLINICS IN LABORATORY MEDICINE (2006)
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
John J. P. Kastelein et al.
CIRCULATION (2006)
Designing siRNA that distinguish between genes that differ by a single nucleotide
Dianne S. Schwarz et al.
PLOS GENETICS (2006)
Liver-specific inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice
Thomas A. Bell et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders
Benoit Viollet et al.
JOURNAL OF PHYSIOLOGY-LONDON (2006)
Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease - Five-year prospective results from the Bruneck study
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance
Roger Gutierrez-Juarez et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
A targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidation
Xiaobo Lin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population
P Yue et al.
HUMAN MUTATION (2006)
Lipoprotein genotype and conserved pathway for exceptional longevity in humans
G Atzmon et al.
PLOS BIOLOGY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2
DB Savage et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol
IK Kotowski et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age
DM Lloyd-Jones et al.
CIRCULATION (2006)
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
C Esau et al.
CELL METABOLISM (2006)
Lack of pharmacokinetic interaction for ISIS 113715, a 2 '-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone
Richard S. Geary et al.
CLINICAL PHARMACOKINETICS (2006)
Cardiovascular disease in the developing world and its cost-effective management
TA Gaziano
CIRCULATION (2005)
Apolipoprotein B:: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis
SO Olofsson et al.
JOURNAL OF INTERNAL MEDICINE (2005)
Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia
RR Sankatsing et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice
XX Yu et al.
HEPATOLOGY (2005)
Antisense oligonucleotides as therapeutics for hyperlipidaemias
RM Crooke
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism
LM Watts et al.
DIABETES (2005)
Familial hypobetalipoproteinemia: genetics and metabolism
G Schonfeld et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
RM Crooke et al.
JOURNAL OF LIPID RESEARCH (2005)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1
GQ Jiang et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
LP Lim et al.
NATURE (2005)
Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs
HJ Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Argonaute2 is the catalytic engine of mammalian RNAi
JD Liu et al.
SCIENCE (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
Minireview: The AMP-activated protein kinase cascade: The key sensor of cellular energy status
DG Hardie
ENDOCRINOLOGY (2003)
CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans
CE Chandler et al.
JOURNAL OF LIPID RESEARCH (2003)
Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders
A Onat et al.
ATHEROSCLEROSIS (2003)
LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients
SJ Lee et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents - A comparative analysis
TA Vickers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure
CA Sueta et al.
JOURNAL OF CARDIAC FAILURE (2003)
Familial combined hyperlipidemia plasma stimulates protein secretion by HepG2 cells: identification of fibronectin in the differential secretion proteome
MMJ van Greevenbroek et al.
JOURNAL OF LIPID RESEARCH (2002)
ATP-binding cassette transporter 1 participates in LDL oxidation by artery wall cells
ST Reddy et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Apolipoprotein E-deficient mice created by systemic administration of antisense oligodeoxynucleotides: a new model for lipoprotein metabolism studies
R Morishita et al.
JOURNAL OF ENDOCRINOLOGY (2002)
Clinical importance of the cytochromes P450
DW Nebert et al.
LANCET (2002)
Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration
DC Chan et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis
CM Rondinone et al.
DIABETES (2002)
Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study)
J Hulthe et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
K Skålén et al.
NATURE (2002)
Design of antisense oligonucleotides stabilized by locked nucleic acids
J Kurreck et al.
NUCLEIC ACIDS RESEARCH (2002)
Hepatic fatty acid synthesis is suppressed in mice with fatty livers due to targeted apolipoprotein B38.9 mutation
X Lin et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Frequency of serum low-density lipoprotein cholesterol measurement and frequency of results ≤ 100 mg/dl among patients who had coronary events (Northwest VA Network study)
KL Sloan et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
SM Elbashir et al.
NATURE (2001)
Insulin resistance and cardiovascular disease
HN Ginsberg
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
